Global Parkinson Disease Drug Competitive Landscape Professional Research Report 2025
Research SummaryParkinson's disease drugs are medications prescribed to individuals diagnosed with Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the brain. These drugs are primarily aimed at alleviating the motor symptoms of the condition, which include tremors, muscle rigidity, and bradykinesia (slowness of movement). The most commonly prescribed class of drugs for Parkinson's disease are levodopa medications, which are converted to dopamine in the brain to help replenish the deficient neurotransmitter. Other drug classes, such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors, are also used to manage symptoms and extend the effectiveness of levodopa. While these drugs can provide significant relief from the motor symptoms, they do not cure Parkinson's disease, and their use may be tailored to each patient's specific needs and stage of the disease.
According to DIResearch's in-depth investigation and research, the global Parkinson Disease Drug market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Parkinson Disease Drug include Merck, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, Roche, Bausch Health, H.Lundbeck, Supernus Pharmaceuticals, Orion, Stada Arzneimittel, Servier, Recordati, Changzhou Kangpu Pharmaceutical Co., Ltd, CSPC Pharmaceutical Group Limited, Zhejiang Jingxin Pharmaceutical Co., Ltd, Qilu Pharmaceutical, YiChang HEC ChangJiang Pharmaceutical Co., Ltd, ZEIN BIOTECHNOLOGY CO., LTD, Hunan Jiudian Pharmaceutical Co., Ltd, Luye Pharma, Shijiazhuang No.4 Pharmaceutical Co.,Ltd etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Parkinson Disease Drug. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Parkinson Disease Drug market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Parkinson Disease Drug market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Parkinson Disease Drug industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Parkinson Disease Drug Include:
Merck
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
Roche
Bausch Health
H.Lundbeck
Supernus Pharmaceuticals
Orion
Stada Arzneimittel
Servier
Recordati
Changzhou Kangpu Pharmaceutical Co., Ltd
CSPC Pharmaceutical Group Limited
Zhejiang Jingxin Pharmaceutical Co., Ltd
Qilu Pharmaceutical
YiChang HEC ChangJiang Pharmaceutical Co., Ltd
ZEIN BIOTECHNOLOGY CO., LTD
Hunan Jiudian Pharmaceutical Co., Ltd
Luye Pharma
Shijiazhuang No.4 Pharmaceutical Co.,Ltd
Parkinson Disease Drug Product Segment Include:
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Others
Parkinson Disease Drug Product Application Include:
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Chapter ScopeChapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Parkinson Disease Drug Industry PESTEL Analysis
Chapter 3: Global Parkinson Disease Drug Industry Porter’s Five Forces Analysis
Chapter 4: Global Parkinson Disease Drug Major Regional Market Size and Forecast Analysis
Chapter 5: Global Parkinson Disease Drug Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Passenger Parkinson Disease Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Parkinson Disease Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Parkinson Disease Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Parkinson Disease Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Parkinson Disease Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Parkinson Disease Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Parkinson Disease Drug Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources